Table 2.
Periodic prevalence of biochemical hypogonadism in the total population and patient groups according to predefined follicle-stimulating hormone (FSH) and testosterone (T) threshold levels.
| Groups | No. of patients | Prevalence (%) | 95% Confidence interval |
|---|---|---|---|
| All patients | |||
| Biochemical hypogonadism | 620/767 | 80.8 | 77.9–83.4 |
| Patient groupsa | |||
| Hypergonadotropic hypogonadal | 325/767 | 42.4 | 38.9–45.9 |
| Normogonadotropic hypogonadal | 295/767 | 38.5 | 35.1–41.9 |
| Hypergonadotropic eugonadal | 64/767 | 8.3 | 6.6–10.5 |
| Normogonadotropic eugonadal | 83/767 | 10.8 | 8.8–13.2 |
a
Hypergonadotropic hypogonadal (elevated FSH and low T), hypergonadotropic eugonadal (elevated FSH and normal T), normogonadotropic hypogonadal (normal FSH and low T), and normogonadotropic eugonadal (normal FSH and normal T).